| 6500- | BCP, | Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis |
| - | in-vitro, | Ovarian, | NA |
| 6501- | BCP, | β-Caryophyllene promotes oxidative stress and apoptosis in KB cells through activation of mitochondrial-mediated pathway - An in-vitro and in-silico study |
| - | in-vitro, | Oral, | KB |
| 6502- | BCP, | Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS) |
| - | Study, | Nor, | NA |
| 6503- | BCP, | The Potential Therapeutic Role of Beta-Caryophyllene as a Chemosensitizer and an Inhibitor of Angiogenesis in Cancer |
| - | Review, | Var, | NA |
| 6504- | BCP, | β-Caryophyllene Induces PPARγ-Mediated Apoptosis and Enhances the Radiosensitivity in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | CT26 | - | in-vitro, | CRC, | HCT116 |
| 6505- | BCP, | Non-clinical toxicity of β-caryophyllene, a dietary cannabinoid: Absence of adverse effects in female Swiss mice |
| - | in-vivo, | Nor, | NA |
| 6506- | BCP, | Multi-Target Protective Effects of β-Caryophyllene (BCP) at the Intersection of Neuroinflammation and Neurodegeneration |
| - | vitro+vivo, | Nor, | HMC3 |
| 6507- | BCP, | Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation |
| - | Review, | AD, | NA |
| 6508- | BCP, | The CB2 Agonist β-Caryophyllene in Male and Female Rats Exposed to a Model of Persistent Inflammatory Pain |
| - | in-vivo, | Nor, | NA |
| 6509- | BCP, | βcaryophyllene oxide induces apoptosis and inhibits proliferation of A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 5510- | bemA, | Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | PC, | NA |
| 5509- | bemA, | Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis |
| - | Review, | Nor, | NA |
| 5511- | bemA, | Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation |
| - | in-vitro, | Var, | NA |
| 5512- | bemA, | Recent advance of ATP citrate lyase inhibitors for the treatment of cancer and related diseases |
| - | Review, | Var, | NA |
| 5513- | bemA, | ACLY inhibition promotes tumour immunity and suppresses liver cancer |
| - | in-vitro, | Liver, | NA |
| 5514- | bemA, | Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients |
| - | Trial, | Nor, | NA |
| 5582- | BetA, | Targeting mitochondrial apoptosis by betulinic acid in human cancers |
| - | Review, | Var, | NA |
| 5593- | BetA, | Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth |
| - | in-vitro, | Lung, | NA |
| 5592- | BetA, | Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa |
| 5591- | BetA, | Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment |
| - | Review, | BC, | NA |
| 5590- | BetA, | Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines |
| - | in-vitro, | HNSCC, | SCC9 | - | in-vitro, | HNSCC, | SCC25 |
| 5589- | BetA, | Advancements in Betulinic Acid-Loaded Nanoformulations for Enhanced Anti-Tumor Therapy |
| - | Review, | Var, | NA |
| 5588- | BetA, | Therapeutic applications of betulinic acid nanoformulations |
| - | Review, | Var, | NA |
| 5587- | BetA, | Rad, | Effects of betulinic acid alone and in combination with irradiation in human melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 5586- | BetA, | Suppression of HIF-1α accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer |
| - | in-vitro, | Cerv, | HeLa |
| 5585- | BetA, | Betulinic acid-induced mitochondria-dependent cell death is counterbalanced by an autophagic salvage response |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | lymphoma, | U937 |
| 5584- | BetA, | Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | U118MG | - | in-vitro, | GBM, | U251 |
| 5583- | BetA, | Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells |
| - | vitro+vivo, | NA, | NA |
| 943- | BetA, | Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 8- | BetA, | Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana |
| - | in-vitro, | PC, | HaCaT | - | in-vitro, | Pca, | PANC1 |
| - | in-vivo, | NA, | NA |
| 2722- | BetA, | Betulinic Acid for Cancer Treatment and Prevention |
| - | Review, | Var, | NA |
| 2723- | BetA, | Betulinic acid and oleanolic acid modulate CD81 expression and induce apoptosis in triple-negative breast cancer cells through ROS generation |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2718- | BetA, | The anti-cancer effect of betulinic acid in u937 human leukemia cells is mediated through ROS-dependent cell cycle arrest and apoptosis |
| - | in-vitro, | AML, | U937 |
| 2721- | BetA, | Proteomic Investigation into Betulinic Acid-Induced Apoptosis of Human Cervical Cancer HeLa Cells |
| - | in-vitro, | Cerv, | HeLa |
| 2720- | BetA, | Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER stress and autophagy in vitro and in vivo |
| - | in-vitro, | Cerv, | HeLa |
| 2719- | BetA, | Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | UMUC3 | - | in-vitro, | Bladder, | 5637 |
| 2734- | BetA, | Betulinic Acid Modulates the Expression of HSPA and Activates Apoptosis in Two Cell Lines of Human Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 2724- | BetA, | Down-regulation of NOX4 by betulinic acid protects against cerebral ischemia-reperfusion in mice |
| - | in-vivo, | Nor, | NA | - | in-vivo, | Stroke, | NA |
| 2725- | BetA, | Betulinic acid protects against renal damage by attenuation of oxidative stress and inflammation via Nrf2 signaling pathway in T-2 toxin-induced mice |
| - | in-vivo, | Nor, | NA |
| 2726- | BetA, | Betulinic acid induces DNA damage and apoptosis in SiHa cells |
| - | in-vitro, | Cerv, | SiHa |
| 2727- | BetA, | Betulinic acid in the treatment of breast cancer: Application and mechanism progress |
| - | Review, | BC, | NA |
| 2728- | BetA, | Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy |
| - | in-vitro, | Var, | NA |
| 2729- | BetA, | Betulinic acid in the treatment of tumour diseases: Application and research progress |
| - | Review, | Var, | NA |
| 2730- | BetA, | Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 2731- | BetA, | Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives |
| - | Review, | GBM, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 2717- | BetA, | Betulinic Acid Induces ROS-Dependent Apoptosis and S-Phase Arrest by Inhibiting the NF-κB Pathway in Human Multiple Myeloma |
| - | in-vitro, | Melanoma, | U266 | - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | RPMI-8226 |
| 2716- | BetA, | Cellular and molecular mechanisms underlying the potential of betulinic acid in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2732- | BetA, | Chemo, | Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78 |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 2733- | BetA, | Betulinic Acid Inhibits Cell Proliferation in Human Oral Squamous Cell Carcinoma via Modulating ROS-Regulated p53 Signaling |
| - | in-vitro, | Oral, | KB | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid